Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A. Macedo AB, et al. Among authors: ren y. JCI Insight. 2018 Oct 4;3(19):e122673. doi: 10.1172/jci.insight.122673. JCI Insight. 2018. PMID: 30282829 Free PMC article.
Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.
Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB. Huang SH, et al. Among authors: ren y. J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22. J Clin Invest. 2018. PMID: 29355843 Free PMC article.
BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo.
Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB. Ren Y, et al. J Clin Invest. 2020 May 1;130(5):2542-2559. doi: 10.1172/JCI132374. J Clin Invest. 2020. PMID: 32027622 Free PMC article.
Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal.
Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CM, Hardy WD, Safrit JT, Jones RB. Mota TM, et al. Among authors: ren y. J Virol. 2020 Apr 16;94(9):e01845-19. doi: 10.1128/JVI.01845-19. Print 2020 Apr 16. J Virol. 2020. PMID: 32051267 Free PMC article.
Selective BCL-XL Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs.
Ren Y, Huang SH, Macedo AB, Ward AR, Alberto WDC, Klevorn T, Leyre L, Copertino DC, Mota TM, Chan D, Truong R, Rohwetter T, Zumbo P, Dündar F, Betel D, Kovacs C, Benko E, Bosque A, Jones RB. Ren Y, et al. J Virol. 2021 Jul 12;95(15):e0242520. doi: 10.1128/JVI.02425-20. Epub 2021 Jul 12. J Virol. 2021. PMID: 33980597 Free PMC article.
Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB. Ren Y, et al. J Virol. 2018 Nov 12;92(23):e00895-18. doi: 10.1128/JVI.00895-18. Print 2018 Dec 1. J Virol. 2018. PMID: 30209173 Free PMC article.
Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV.
Powell AB, Ren Y, Korom M, Saunders D, Hanley PJ, Goldstein H, Nixon DF, Bollard CM, Lynch RM, Jones RB, Cruz CRY. Powell AB, et al. Among authors: ren y. Mol Ther Methods Clin Dev. 2020 Aug 21;19:78-88. doi: 10.1016/j.omtm.2020.08.015. eCollection 2020 Dec 11. Mol Ther Methods Clin Dev. 2020. PMID: 33005704 Free PMC article.
13,221 results
You have reached the last available page of results. Please see the User Guide for more information.